Laboratorios Farmaceuticos Rovi reported earnings for the nine months to 30 September 2026, with sales of €610.17 million and net income of €162.89 million, compared with €525.06 million and €97.77 million respectively in the prior-year period. The stronger combination of revenue and profit for the period suggests that Laboratorios Farmaceuticos Rovi is converting its product mix and CDMO capacity investments into higher earnings, despite previous concerns around heparin pricing and R&D…